2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Radionuclide-Drug Conjugates (RDCs)
  5. RDC Antibody Isoform

RDC Antibody

RDC antibodies function as antigen-binding carriers that direct radionuclides to cancer-associated cell-surface targets for imaging or therapy[1]. Mechanistically, radioimmunotherapy uses monoclonal antibodies to deliver particulate radiation to tumor cells while limiting normal-tissue exposure[1][2]. Compared with small-molecule or peptide RDC vectors, intact antibodies provide high antigen specificity but require pharmacokinetic engineering to optimize circulation, tumor penetration, and clearance[3][4]. In disease models and clinical studies, antibody-radionuclide conjugates have been applied to lymphoma and solid-tumor targets, including CD45-targeted lymphoma treatment and mesothelin-targeted thorium-227 therapy[5][6]. For RDC antibody design, the key distinction from antibody fragments is that intact IgG supports prolonged exposure, whereas engineered fragments can improve tissue penetration and imaging contrast[3][4].- Select antigens with tumor enrichment, stable expression, and compatibility with antibody biodistribution.- Match antibody format, chelator, and radionuclide half-life to imaging or therapy goals.

RDC Antibody Related Products (8):

Cat. No. Product Name Effect Purity
  • HY-P9907
    Trastuzumab
    		99.80%
    Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer. (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)
  • HY-P9905
    Cetuximab
    		99.81%
    Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity.
  • HY-P9913
    Rituximab
    		99.85%
    Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.
  • HY-P99239
    Rosopatamab
    		99.50%
    Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 (177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency.
  • HY-P9983
    Lintuzumab
    		98.09%
    Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice.
  • HY-P992475
    Tecnemab K1
    Tecnemab K1 is an anti-Melanoma monoclonal antibody. Tecnemab K1 accumulates in metastatic lesions of malignant melanoma and some benign lesions. When radiolabeled, Tecnemab K1 can serve as a radiotracer for malignant melanoma research. The isotype control is Mouse IgG1 kappa, Isotype Control (HY-P99977).
  • HY-P992090
    Altumomab
    Altumomab is a anti-huamn monoclonal antibody targeting CEACAM5/CEA/CD66e.
  • HY-P99581
    Tabituximab barzuxetan (exclude Y90)
    Tabituximab barzuxetan (exclude Y90) (OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01) is a immunoconjugate composed of a humanized monoclonal antibody targeting FZD-10 (OTSA-101). Tabituximab barzuxetan exhibits anti-tumor activity. Tabituximab barzuxetan can be used for the research of synovial sarcoma.